Should the number of acute exacerbations in the previous year be used to guide treatments in COPD?
Mohsen Sadatsafavi, James McCormack, John Petkau, Larry D. Lynd, Tae Yoon Lee, Don D. Sin
European Respiratory Journal 2021 57: 2002122; DOI: 10.1183/13993003.02122-2020
Mohsen Sadatsafavi
1Respiratory Evaluation Sciences Program, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada
2Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada
3UBC Centre for Heart Lung Innovation and Dept of Medicine (Respirology), University of British Columbia, Vancouver, BC, Canada
James McCormack
2Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada
John Petkau
4Dept of Statistics, University of British Columbia, Vancouver, BC, Canada
Larry D. Lynd
2Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada
5Centre for Health Evaluation and Outcome Sciences, Providence Healthcare Research Institute, Vancouver, BC, Canada
Tae Yoon Lee
1Respiratory Evaluation Sciences Program, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada
2Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada
Don D. Sin
3UBC Centre for Heart Lung Innovation and Dept of Medicine (Respirology), University of British Columbia, Vancouver, BC, Canada
Vol 57 Issue 2
Table of Contents
Should the number of acute exacerbations in the previous year be used to guide treatments in COPD?
Mohsen Sadatsafavi, James McCormack, John Petkau, Larry D. Lynd, Tae Yoon Lee, Don D. Sin
European Respiratory Journal Feb 2021, 57 (2) 2002122; DOI: 10.1183/13993003.02122-2020